The city of Cincinnati, Ohio, currently has 6 active clinical trials seeking participants for Parkinson's Disease research studies.
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
Recruiting
The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls. The overall goal of PPMI is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
01/16/2025
Locations: University of Cincinnati/Cincinnati Children's Hospital, Cincinnati, Ohio
Conditions: Parkinson Disease
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
Recruiting
This is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations. Participants will be randomized to receive once-daily oral doses of either 75 milligrams (mg) CVN424, 150 mg CVN424, or a matching placebo for 12 weeks. Participants who successfully complete this study and retain eligibility/suitability will be invited to participate in a future open-label extension (OLE) study.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
12/19/2024
Locations: Riverhills Healthcare, Inc dba Riverhills Neuroscience, Cincinnati, Ohio
Conditions: Parkinson Disease
Study in Parkinson Disease of Exercise
Recruiting
This study is a Phase 3 multi-site, randomized, evaluator-masked, study of endurance treadmill exercise on changes in the Movement Disorder Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part III score at 12 months among persons with early stage Parkinson disease. 370 participants will be randomly assigned to 2 groups: 1)60-65% HRmax or 2)80-85% HRmax 4 times per week. The primary objective is to test whether the progression of the signs of Parkinson's disease is attenuated at 12 mon... Read More
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
11/12/2024
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Parkinson Disease
Trial of Parkinson's and Zoledronic Acid
Recruiting
This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 3500 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the Nationa... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
09/03/2024
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Parkinson Disease, Osteoporosis, Parkinsonism, Parkinson's Disease and Parkinsonism, Atypical Parkinsonism, Progressive Supranuclear Palsy, Multiple System Atrophy, Vascular Parkinsonism, Dementia With Lewy Bodies
Parkinson's Foundation PD GENEration Genetic Registry
Recruiting
Development of a central repository for PD-related genomic data for future research.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/28/2024
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Parkinson's Disease
The Parkinson's Genetic Research Study
Recruiting
The Parkinson's Genetic Research Study (PaGeR), headed by Dr. Cyrus Zabetian, is searching for genes that increase the risk of developing Parkinson's disease (PD) and related disorders. The study is a joint effort by neurologists and researchers across the United States and is sponsored by the National Institutes of Health. The coordinating center for PaGeR is located at the University of Washington and the VA Puget Sound Health Care System in Seattle.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/11/2024
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Parkinson's Disease